Pacira BioSciences completed the acquisition of the remaining shares in GQ Bio for $32m.

Pacira BioSciences, a biopharmaceutical company that focuses on developing and commercializing non-opioid pain management solutions, completed the acquisition of the remaining shares in GQ Bio, a biotechnology company focused on developing innovative treatments for cancer and other diseases, for $32m. "We are confident that this transaction will enhance our ability to address unmet patient needs, while building on our 5x30 plan to transition into an innovative biopharmaceutical organization. We have seen GQ Bio’s platform generate encouraging clinical data with PCRX-201 in osteoarthritis, underscoring the potential of this novel platform," Frank D. Lee, Pacira BioSciences CEO.